Abstract

BackgroundMeningococcal serogroup A conjugate vaccine (MACV) was introduced in 2017 into the routine childhood immunization schedule (at 15–18 months of age) in Burkina Faso to help reduce meningococcal meningitis burden. MACV was scheduled to be co-administered with the second dose of measles-containing vaccine (MCV2), a vaccine already in the national schedule. One year following the introduction of MACV, an assessment was conducted to qualitatively examine health workers’ perceptions of MACV introduction, identify barriers to uptake, and explore opportunities to improve coverage.MethodsTwelve in-depth interviews were conducted with different cadres of health workers in four purposively selected districts in Burkina Faso. Districts were selected to include urban and rural areas as well as high and low MCV2 coverage areas. Respondents included health workers at the following levels: regional health managers (n = 4), district health managers (n = 4), and frontline healthcare providers (n = 4). All interviews were recorded, transcribed, and thematically analyzed using qualitative content analysis.ResultsFour themes emerged around supply and health systems barriers, demand-related barriers, specific challenges related to MACV and MCV2 co-administration, and motivations and efforts to improve vaccination coverage. Supply and health systems barriers included aging cold chain equipment, staff shortages, overworked and poorly trained staff, insufficient supplies and financial resources, and challenges with implementing community outreach activities. Health workers largely viewed MACV introduction as a source of motivation for caregivers to bring their children for the 15- to 18-month visit. However, they also pointed to demand barriers, including cultural practices that sometimes discourage vaccination, misconceptions about vaccines, and religious beliefs. Challenges in co-administering MACV and MCV2 were mainly related to reluctance among health workers to open multi-dose vials unless enough children were present to avoid wastage.ConclusionsTo improve effective administration of vaccines in the second-year of life, adequate operational and programmatic planning, training, communication, and monitoring are necessary. Moreover, clear policy communication is needed to help ensure that health workers do not refrain from opening multi-dose vials for small numbers of children.

Highlights

  • Meningococcal serogroup A conjugate vaccine (MACV) was introduced in 2017 into the routine childhood immunization schedule in Burkina Faso to help reduce meningococcal meningitis burden

  • Based on the structured In-depth interview (IDI), the four major themes that emerged were related to supply and health systems barriers, demand-related barriers, specific challenges related to MACV and second dose of measles-containing vaccine (MCV2) co-administration, and motivations and efforts to improve vaccination coverage

  • “There are others who take advantage of mosquito nets that are given to health facilities for children under 5 years old and pregnant women, to motivate mothers during immunization sessions.” – Expanded Program on Immunization (EPI) Manager at district level. These findings reveal various factors that contribute to vaccine uptake after the introduction of MACV in the routine childhood immunization program in Burkina Faso, as well as challenges faced by health workers conducting vaccination programs for children during their second year of life in general

Read more

Summary

Introduction

Meningococcal serogroup A conjugate vaccine (MACV) was introduced in 2017 into the routine childhood immunization schedule (at 15–18 months of age) in Burkina Faso to help reduce meningococcal meningitis burden. Serogroup A has historically been the cause of epidemic meningitis in sub-Saharan Africa and predominantly affects people < 30 years of age [3]. To help reduce the meningococcal meningitis burden in endemic African countries, meningococcal serogroup A conjugate vaccine (MACV, MenAfriVacTM) was introduced beginning in 2010 through mass vaccination campaigns for people from age 1 to 29 years [5]. The incidence of serogroup A meningitis declined sharply following MACV mass vaccination campaigns in these countries, including Burkina Faso [6]. High community acceptance of MACV was reported during the campaigns [7] and resulted in nearly 100% coverage of MACV, based on administrative data from the campaigns

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call